Patents by Inventor Pijus Kumar MANDAL

Pijus Kumar MANDAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230008047
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: May 21, 2021
    Publication date: January 12, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • Imidazopiperazine inhibitors of transcription activating proteins
    Patent number: 11058688
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 13, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Philip Jones, Jason Bryant Cross, Christopher L. Carroll, Timothy Joseph McAfoos, Pijus Kumar Mandal
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190298729
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 3, 2019
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • STAT6 inhibitors
    Patent number: 10385080
    Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 20, 2019
    Assignees: Board of Regents, The University of Texas System, Baylor College of Medicine
    Inventors: John S. McMurray, Pijus Kumar Mandal, Pietro Morlacchi, Morgan Knight, David B. Corry
  • STAT6 INHIBITORS
    Publication number: 20180222931
    Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
    Type: Application
    Filed: August 16, 2017
    Publication date: August 9, 2018
    Applicants: Board of Regents, The University of Texas System, Baylor College of Medicine
    Inventors: John S. McMURRAY, Pijus Kumar MANDAL, Pietro MORLACCHI, Morgan KNIGHT, David B. CORRY
  • STAT6 inhibitors
    Patent number: 9765099
    Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: September 19, 2017
    Assignees: Board of Regents, The University of Texas System, Baylor College of Medicine
    Inventors: John S. McMurray, Pijus Kumar Mandal, Pietro Morlacchi, Morgan Knight, David B. Corry
  • STAT6 INHIBITORS
    Publication number: 20160145279
    Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
    Type: Application
    Filed: May 8, 2014
    Publication date: May 26, 2016
    Applicants: Baylor College of Medicine, Board of Regents, The University of Texas System
    Inventors: John S. McMURRAY, Pijus Kumar MANDAL, Pietro MORLACCHI, Morgan KNIGHT, David B. CORRY